We've had an excellent experience collaborating with FI Group. Their team of consultants demonstrated proficiency in evaluating and comprehending our innovative wave energy technology, leading to a comprehensive technical report that played a significant role in securing our R&D tax credit repayment.
LSIMF | Life Sciences Innovative Manufacturing Fund | UK Life Sciences Grants
LSIMF – Life Sciences Innovative Manufacturing Fund: A Strategic Guide
The Life Sciences Manufacturing Fund (LSIMF), also known as the Life Sciences Innovative Manufacturing Fund (LSIMF), is a UK Government capital grant programme designed to accelerate high-value manufacturing in life sciences. Worth £520 million between 2025 and 2030, it supports UK-based businesses investing in human medicines, medical diagnostics, and MedTech manufacturing.
With FI Group’s Global Reach, Local Expertise, we help you navigate every stage of the process, ensuring your application clearly demonstrates the health resilience, economic impact, and innovation that LSMF assessors prioritise.
What is the Life Sciences Innovative Manufacturing Fund (LSIMF)?
The Life Sciences Innovative Manufacturing Fund is a UK capital grant scheme supporting manufacturing projects for medicines, diagnostics, and MedTech that strengthen UK health resilience and create high-skilled jobs. Grants typically cover 10–25% of capital costs for projects worth at least £8 million.
The fund builds on the UK’s Life Sciences Vision and Industrial Strategy, encouraging growth, sustainability, and competitiveness across the sector.
Quick Facts – LSIMF at a Glance
Be the first to know
| Category | Details |
|---|---|
| Total Funding | £520 million (2025–2030) |
| Eligible Sectors | Human medicines, medical diagnostics, MedTech manufacturing |
| Minimum Project Cost | £8 million |
| Grant Size | Typically 10–25% of eligible capital costs |
| Eligible Applicants | UK-registered companies (developers, CDMOs, generics manufacturers) |
| Application Method | Rolling Expressions of Interest + quarterly assessment rounds |
Why LSIMF Matters for UK Health & Economy
The fund aims to deliver lasting benefits across four strategic objectives:
-
Strengthen UK health resilience by expanding domestic production of essential medicines and diagnostics
-
Create and safeguard high-skilled jobs in advanced manufacturing
-
Drive innovation through investment in cutting-edge facilities and processes
-
Support sustainability and net zero targets within life sciences manufacturing
Who Can Apply – LSIMF Eligibility Criteria
| Company-Level Criteria | Project-Level Criteria |
|---|---|
| UK-registered, private-sector organisation | Located in the UK |
| Product developers, CDMOs, or generics manufacturers | Capital-intensive manufacturing investment |
| Financially viable | Minimum total cost £8 million |
| Able to demonstrate need for grant funding | Single-company projects (not consortiums) |
Get the Global View, Download our International Grants Guide 2025
FI Group’s International Grants Guide 2025 is an invaluable resource for CFOs navigating complex funding landscapes. It maps out public grant opportunities across 18+ countries.
Why CFOs find it useful:
-
Highlights key national and European schemes, including Horizon Europe and RRF
-
Helps you align funding strategy with board-level objectives
-
Supports cross-border planning with FI Group’s presence in 20 countries
Get the Global View, Download our International Grants Guide 2025
FI Group’s International Grants Guide 2025 is an invaluable resource for CFOs navigating complex funding landscapes. It maps out public grant opportunities across 18+ countries.
Why CFOs find it useful:
-
Highlights key national and European schemes, including Horizon Europe and RRF
-
Helps you align funding strategy with board-level objectives
-
Supports cross-border planning with FI Group’s presence in 20 countries
Step-by-Step
LSIMF Application Process & Timeline
The Life Sciences Innovative Manufacturing Fund uses a multi-stage application process. Each stage requires precise evidence, strategic positioning, and compliance with UK Government funding requirements. This is where FI Group’s Global Reach, Local Expertise ensures your application stands out.
Grant Value & Intervention Rates
The grant covers a proportion of eligible capital expenditure:
-
SMEs: up to 25% of costs
-
Large companies: typically 10–20%
-
No absolute maximum cap, but funding is awarded competitively and aligned to State Aid rules
Successful LSIMF Projects & Outcomes
| Company | Investment | Focus Area | Jobs Created | Jobs Safeguarded |
|---|---|---|---|---|
| Ipsen | £75m | Neurological medicines manufacturing | 39 | 37 |
| Pharmaron | £151m | Gene therapy & vaccine manufacturing | 174 | 156 |
| Touchlight | £14m | DNA manufacturing | 17 | 6 |
| Randox | £36m | Antibody diagnostics facility (NI) | N/A | N/A |
How FI Group Can Maximise Your LSIMF Application Success
Our Grants Roadmapping service ensures your LSIMF application is competitive from the outset. We combine sector-specific insight with application precision, guiding you through eligibility, scoping, documentation, and submission.
“With our technical and regulatory expertise, we anticipate what assessors need to see. We ensure your project clearly demonstrates health resilience and economic impact, presenting it with clarity and authority every step of the way.”
– Dr. Fawzi Abou-Chahine, Funding Director, FI Group UK
How FI Group Can Maximise Your LSIMF Application Success
Our Grants Roadmapping service ensures your LSIMF application is competitive from the outset. We combine sector-specific insight with application precision, guiding you through eligibility, scoping, documentation, and submission.
“With our technical and regulatory expertise, we anticipate what assessors need to see. We ensure your project clearly demonstrates health resilience and economic impact, presenting it with clarity and authority every step of the way.”
– Dr. Fawzi Abou-Chahine, Funding Director, FI Group UK
Frequently Asked Questions (FAQs)
Life Sciences Innovative Manufacturing Fund
Before applying for the Life Sciences Innovative Manufacturing Fund (LSIMF), many businesses have common questions about eligibility, funding levels, timelines, and requirements. Our experts have answered the most frequent queries below, providing detailed guidance to help you prepare a strong and compliant application.
Book A MeetingWith A PhD Expert
Spotlight on Success: Stablepharma Secures €2.5M Through the EIC Accelerator
In early 2025, Stablepharma Ltd was awarded €2.5 million in grant funding through the EIC Accelerator to advance its StablevaX™ technology, an innovation set to transform vaccine distribution by removing the need for cold‑chain logistics.
FI Group UK played a pivotal role in reviewing and strengthening the company’s final submission. Working closely with Stablepharma’s executive team, FI Group helped refine the technical narrative, align financials with key clinical milestones, and enhance the overall credibility and clarity of the application. The award made Stablepharma one of just five UK companies selected in a highly competitive round of over 1,200 applicants.
This success highlights how expert grant consultancy can significantly improve outcomes for high-potential applicants seeking funding under Horizon Europe’s most competitive instruments.
Spotlight on Success: Stablepharma Secures €2.5M Through the EIC Accelerator
In early 2025, Stablepharma Ltd was awarded €2.5 million in grant funding through the EIC Accelerator to advance its StablevaX™ technology, an innovation set to transform vaccine distribution by removing the need for cold‑chain logistics.
FI Group UK played a pivotal role in reviewing and strengthening the company’s final submission. Working closely with Stablepharma’s executive team, FI Group helped refine the technical narrative, align financials with key clinical milestones, and enhance the overall credibility and clarity of the application. The award made Stablepharma one of just five UK companies selected in a highly competitive round of over 1,200 applicants.
This success highlights how expert grant consultancy can significantly improve outcomes for high-potential applicants seeking funding under Horizon Europe’s most competitive instruments.
What Our Clients Say
Leading innovators across the UK, from deep-tech start-ups to large research-driven corporates, trust FI Group to guide their most strategic grant bids. Our tailored support has helped secure multi-million euro awards through Horizon Europe, the EIC Accelerator, and Innovate UK. Clients return to us year after year for our end-to-end delivery, strategic insight, and deep evaluator understanding.
The smoothest way to work on R&D Tax Credit – not only are they experts of the subject but also sectors specialists; FI Group could get all the technical elements of our business by themselves leading to a successful and remarkable result.
Giuseppe Amoroso from FI group did our R&D tax claim and successfully submitted on our behalf of OxDevice. Excellent team work in Submitting the claim.
Partner with FI Group for LSIMF SuccessBook A Meeting
Before applying for the Life Sciences Innovative Manufacturing Fund (LSIMF), many businesses have common questions about eligibility, funding levels, timelines, and requirements. Our experts have answered the most frequent queries below and can provide tailored support through:
-
Bid Writing Services – Crafting compelling, compliant, and assessor-ready applications
-
UK Grant Competitions – Identifying and securing the right funding opportunities beyond LSIMF
-
Horizon Europe Grant Support – Leveraging our EU-wide network to access collaborative funding for international projects
